A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: A potential osteoclastogenesis inhibitor for experimental arthritis

Journal of Clinical Immunology

Volumn 32, Issue 4, 2012, Pages 762-777

  Cheng, Chia Pi ^a   Huang, Hsu Shan ^a   Hsu, Yu Chieh ^b   Sheu, Ming Jen ^c   Chang, Deh Ming ^b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Collagen induced arthritis; NFATc1; Osteoclast; Salicylic acid

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BENZAMIDE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; N (4 CHLORO 2 FLUOROPHENYL) 2 HYDROXYBENZAMIDE; NDMC 101; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFATC1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE EROSION; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYNOVITIS;

ACID PHOSPHATASE; ANIMALS; ARTHRITIS, EXPERIMENTAL; BENZAMIDES; CELL DIFFERENTIATION; CELL LINE; COLLAGEN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; INFLAMMATION; INTERLEUKIN-1BETA; ISOENZYMES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MACROPHAGES; MICE; MICE, INBRED DBA; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RANK LIGAND; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863986849     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9660-9     Document Type: Article

References (40)

1. Goltzman D. Discoveries, drugs and skeletal disorders. Nat Rev Drug Discov. 2002;1(10):784-96. (Pubitemid 37361562)
2. Suda T, Takahashi N, Martin TJ. Modulation of osteoclast differentiation. Endocr Rev. 1992;13(1):66-80.
3. Yao GQ, Sun B, Hammond EE, Spencer EN, Horowitz MC, Insogna KL, et al. The cell-surface form of colony-stimulating factor-1 is regulated by osteotropic agents and supports formation of multinucleated osteoclast-like cells. J Biol Chem. 1998;273 (7):4119-28. (Pubitemid 28103280)
4. Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB. Characterization of the intracellular domain of receptor activator of NFkappaB (RANK). Interaction with tumor necrosis factor receptorassociated factors and activation of NF-kappab and c-Jun Nterminal kinase. J Biol Chem. 1998;273(32):20551-5. (Pubitemid 28377625)
5. Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J Biol Chem. 1998;273 (43):28355-9. (Pubitemid 28496137)
6. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone. 2007;40(2):251-64. (Pubitemid 46054562)
7. Raisz LG. Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and disease. Am J Med. 2001;110(Suppl 3A):43S-5S. (Pubitemid 32155402)
8. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A. 1994;91(8):3228-32. (Pubitemid 24130209)
9. Flower RJ. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev. 1974;26(1):33-67.
10. Lipsky PE, Brooks P, Crofford LJ, DuBois R, Graham D, Simon LS, et al. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med. 2000;160(7):913-20. (Pubitemid 30191918)
11. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001;15(12):2057-72. (Pubitemid 32927924)
12. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265(5174):956-9.
13. Liu FC, Huang HS, Huang CY, Yang R, Chang DM, Lai JH et al. A benzamide-linked small molecule HS-Cf inhibits TNF-alphainduced interferon regulatory factor-1 in porcine chondrocytes: A potential disease-modifying drug for osteoarthritis therapeutics. J Clin Immunol. 31(6):1131-42.
14. Ju JH, Cho ML, Moon YM, Oh HJ, Park JS, Jhun JY, et al. IL-23 induces receptor activator of NF-kappaB ligand expression on CD4+ T cells and promotes osteoclastogenesis in an autoimmune arthritis model. J Immunol. 2008;181(2):1507-18.
15. Evans KE, Fox SW. Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus. BMC Cell Biol. 2007;8:4.
16. Park MJ, Min SY, Park KS, Cho YG, Cho ML, Jung YO, et al. Indoleamine 2,3-dioxygenase-expressing dendritic cells are involved in the generation of CD4+ CD25+ regulatory T cells in Peyer's patches in an orally tolerized, collagen-induced arthritis mouse model. Arthritis Res Ther. 2008;10(1):R11.
17. Campo GM, Avenoso A, Campo S, Ferlazzo AM, Altavilla D, Calatroni A. Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthritis Res Ther. 2003;5(3):R122-31.
18. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med. 2005;11 (9):936-43. (Pubitemid 41294438)
19. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol. 2001;159(5):1689-99. (Pubitemid 33062512)
20. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: Comparison of efficacy in animal models with human clinical data. Arthritis Rheum. 1999;42(3):498-506. (Pubitemid 29136098)
21. Lee SE, Woo KM, Kim SY, Kim HM, Kwack K, Lee ZH, et al. The phosphatidylinositol 3-kinase, p38, and extracellular signalregulated kinase pathways are involved in osteoclast differentiation. Bone. 2002;30(1):71-7. (Pubitemid 34044303)
22. Mozar A, Haren N, Chasseraud M, Louvet L, Maziere C,Wattel A, et al. High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells. J Cell Physiol. 2008;215(1):47-54. (Pubitemid 351363190)
23. Shiotani A, Takami M, Itoh K, Shibasaki Y, Sasaki T. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. Anat Rec. 2002;268(2):137-46.
24. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3(6):889-901. (Pubitemid 35460788)
25. Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, et al. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem. 2007;282(25):18245-53. (Pubitemid 47100255)
26. Ishida N, Hayashi K, Hoshijima M, Ogawa T, Koga S, Miyatake Y, et al. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem. 2002;277(43):41147-56. (Pubitemid 35215706)
27. van den Berg WB, van Lent PL, Joosten LA, Abdollahi-Roodsaz S, Koenders MI. Amplifying elements of arthritis and joint destruction. Ann Rheum Dis. 2007;66 Suppl 3:iii45-8. (Pubitemid 350032633)
28. Scrivo R, Di Franco M, Spadaro A, Valesini G. The immunology of rheumatoid arthritis. Ann N Y Acad Sci. 2007;1108:312-22. (Pubitemid 47528744)
29. Ritsema T, van Zanten M, Leon-Reyes A, Voesenek LA, Millenaar FF, Pieterse CM et al. Kinome profiling reveals an interaction between jasmonate, salicylate and light control of hyponastic petiole growth in Arabidopsis thaliana. PLoS One. 5(12):e14255.
30. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998;396(6706):77-80. (Pubitemid 28520452)
31. Ang ES, Pavlos NJ, Chai LY, Qi M, Cheng TS, Steer JH, et al. Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity. J Cell Physiol. 2009;221(3):642-9.
32. Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE, et al. Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activationinduced cytokine-mediated osteoclastogenesis. J Biol Chem. 2005;280(42):35209-16. (Pubitemid 41532708)
33. Kukita T, Wada N, Kukita A, Kakimoto T, Sandra F, Toh K, et al. RANKL-induced DC-STAMP is essential for osteoclastogenesis. J Exp Med. 2004;200(7):941-6. (Pubitemid 39362930)
34. Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, Fujita N, et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med. 2005;202 (3):345-51. (Pubitemid 41126951)
35. Zou W, Kitaura H, Reeve J, Long F, Tybulewicz VL, Shattil SJ, et al. Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol. 2007;176(6):877-88. (Pubitemid 46425547)
36. Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I, et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med. 2004;10 (6):617-24. (Pubitemid 38796853)
37. Mino T, Sugiyama E, Taki H, Kuroda A, Yamashita N, Maruyama M, et al. Interleukin-1alpha and tumor necrosis factor alpha synergistically stimulate prostaglandin E2-dependent production of interleukin-11 in rheumatoid synovial fibroblasts. Arthritis Rheum. 1998;41(11):2004-13. (Pubitemid 28506691)
38. Han KY, Yang D, Chang EJ, Lee Y, Huang H, Sung SH, et al. Inhibition of osteoclast differentiation and bone resorption by sauchinone. Biochem Pharmacol. 2007;74(6):911-23. (Pubitemid 47212083)
39. Ritchlin C. Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis. Arthritis Res. 2000;2(5):356-60. (Pubitemid 32223764)
40. Warren JS. Interleukins and tumor necrosis factor in inflammation. Crit Rev Clin Lab Sci. 1990;28(1):37-59. (Pubitemid 20280624)